Evercore ISI cuts MNTN stock rating on revenue miss, management changes

MNTN reported Q3 revenue of $80.3 million, up 15% year over year but 8% below Wall Street estimates, and forecast Q4 revenue of $75 million to $78 million, implying a 12% year-over-year decline at the midpoint. It cut fiscal 2026 revenue guidance to $311 million–$314 million from $347 million–$357 million and adjusted EBITDA guidance to $66 million–$68 million from $96 million–$101 million; the board replaced the CEO, COO and CRO after go-to-market execution problems. Evercore ISI downgraded the stock to In Line from Outperform and cut its target to $7 from $22; MNTN remained profitable over the trailing 12 months, with gross margin at 79% and existing-customer expansion above 115%.

Analysis

The key risk is not simply a weak quarter; it is whether a sales-compensation change and leadership turnover damaged new-customer acquisition enough to turn a temporary execution miss into a multi-quarter growth reset. Existing-customer expansion and stable gross margin are evidence against broad product deterioration, but they do not establish that new bookings or renewal economics are intact. Watch those separately.

The reset also raises a quality-of-earnings concern: midpoint FY2026 adjusted EBITDA guidance fell roughly 32% from the prior midpoint, versus an approximately 11% revenue reduction. That widening gap suggests less operating leverage than investors had underwritten; management must explain whether this is temporary sales disruption, added remediation expense, or a structurally higher cost to sell. The cited low EV/EBITDA multiple offers limited comfort if the EBITDA denominator remains at risk, while net cash reduces near-term balance-sheet pressure rather than fixing execution.

Near term, leadership handoff and another weak seasonal quarter can keep estimates under pressure. Over 1–3 months, the decisive evidence is sales-force stability, bookings/new-logo trends, and whether guidance stops moving down. Over 6–18 months, recovery depends on rebuilding selling capacity without impairing customer expansion. Contrarian upside exists if the customer base continues expanding and new sales productivity recovers; the expansion metric alone is not proof of that recovery. No trade should rely on the broker target or a single quarter as a valuation floor.

Key Decisions for Investors

• Keep MNTN underweight and avoid treating the low headline multiple as a catalyst. Consider a short only on a failed relief rally or another downward estimate revision; do not chase weakness before the new CEO provides operating detail, given cash on hand and the possibility that the disruption is reversible.
• Use the next earnings update and management commentary as the 1–3 month catalyst check: require evidence on sales-force retention, new-customer bookings, and pipeline conversion—not just existing-customer expansion—before adding long exposure.
• Falsify the bearish thesis if sales attrition stabilizes, new-logo momentum returns, and revenue guidance holds or improves while customer expansion remains healthy. Renew the downside case if bookings weaken further or adjusted EBITDA guidance is cut again; verify the source and sustainability of the reported expansion rate before assigning it substantial weight.